Friday, June 19, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

XPeng’s X9 Dominates Norwegian Range Test, but European Launch Fails to Ignite Stock

SiterGedge by SiterGedge
June 19, 2026
in Analysis, Automotive & E-Mobility, European Markets
0
XPeng Stock
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

The Chinese electric-vehicle maker XPeng has kicked off sales of its flagship X9 van across Europe, but the premium model’s impressive real-world range performance has done little to arrest the stock’s lingering slide. Shares edged up to €11.86 on Friday as markets welcomed the rollout in Germany and Norway, yet the gain remains a shallow bounce from the 52-week low of €11.32 touched just a day earlier.

It is the X9’s charging and range credentials that are generating the most buzz. In the renowned Norwegian El Prix—the world’s largest independent EV test for range and charging speed—the seven-seater covered 646 kilometres under real conditions, beating its own WLTP estimate by 11.4%. The company’s official maximum WLTP range for the model is listed at 615 km, meaning the test vehicle outperformed even that figure. At the fast-charger, the X9 replenished a substantial portion of its battery in under 13 minutes, with a peak charging capacity of 542 kilowatts—so powerful that Norwegian infrastructure could not fully tap it.

Such technical bragging rights are vital for XPeng as it tries to carve out a premium niche in Europe. Pricing starts at approximately €77,600 for the standard version and climbs to nearly €87,000 for the all-wheel-drive top spec. Yet the charging bottleneck on this side of the Atlantic remains a challenge: most European chargers are capped at 400 kW, leaving the X9’s theoretical maximum untapped.

Should investors sell immediately? Or is it worth buying XPeng?

Operationally, XPeng is fighting a tougher battle. First-quarter deliveries slumped by a third year-on-year to just over 62,600 vehicles, dragging revenue down to around 13 billion renminbi—a near-18% decline. The net loss widened to 1.78 billion renminbi, though the company’s cash pile remains healthy at more than 42 billion renminbi. One bright spot is profitability: gross margin improved to 20.6% in the first quarter, up sharply from the prior year, as cost controls and a shift toward higher-margin models begin to pay off.

The market, however, remains unconvinced. The stock has lost roughly a third of its value since January, and the key 200-day moving average sits near €17—a far cry from current levels. Management is banking on the X9 to help turn the tide, with a target of at least 100,000 vehicle deliveries in the second quarter. The van will also reach UK showrooms later in 2026.

For now, XPeng has proven its technology can hold its own against the best. The challenge is converting that credibility into sales numbers that will lift the share price off the floor.

Ad

XPeng Stock: Buy or Sell?! New XPeng Analysis from June 19 delivers the answer:

The latest XPeng figures speak for themselves: Urgent action needed for XPeng investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 19.

XPeng: Buy or sell? Read more here...

Tags: XPeng
SiterGedge

SiterGedge

Related Posts

Vital Farms Stock
Analysis

Vital Farms Faces Twin Storms: Legal Investigation and Institutional Flight

June 19, 2026
Kuros Biosciences Stock
Analysis

Kuros Biosciences: Revenue Surges 72% But Shares Sink to 52-Week Low

June 19, 2026
Outlook Therapeutics Stock
Analysis

Outlook Therapeutics’ July 16 Shareholder Vote to Decide Nasdaq Fate as FDA Decision Looms on July 29

June 19, 2026
Next Post
Outlook Therapeutics Stock

Outlook Therapeutics' July 16 Shareholder Vote to Decide Nasdaq Fate as FDA Decision Looms on July 29

CEREBRAS SYSTEMS INC - A Stock

Cerebras Races Into First Earnings Report After Back-to-Back Double-Digit Gains

Medtronic Stock

Medtronic's Asian Push and Portfolio Reshuffle Fail to Lift Stock from Its Lows

Recommended

Tyler Stock

Institutional Investors Recalibrate Stakes in Government Software Provider

5 months ago
Trinet Stock

Trinet Stock: A Study in Contradictions Amid Steep Decline

10 months ago
Strategy Stock

Conflicting Signals Leave Strategy Investors at a Crossroads

9 months ago
Vulcan Energy Stock

Vulcan Energy Powers Europe’s Lithium Independence Drive

7 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Kuros Biosciences: Revenue Surges 72% But Shares Sink to 52-Week Low

Medtronic’s Asian Push and Portfolio Reshuffle Fail to Lift Stock from Its Lows

Cerebras Races Into First Earnings Report After Back-to-Back Double-Digit Gains

Outlook Therapeutics’ July 16 Shareholder Vote to Decide Nasdaq Fate as FDA Decision Looms on July 29

XPeng’s X9 Dominates Norwegian Range Test, but European Launch Fails to Ignite Stock

ServiceNow’s Q1 Revenue Jumps 22% as AI Bet Pays Off, but Armis Price Tag Weighs on Margins

Trending

Rocket Lab USA Stock
Industrial

Rocket Lab’s New Phase: Index Entry and Robotics M&A Converge to Reshape the Investment Thesis

by Rodolfo Hanigan
June 19, 2026
0

Monday will bring Rocket Lab a structural shift that no single launch can match. The stock joins...

Vital Farms Stock

Vital Farms Faces Twin Storms: Legal Investigation and Institutional Flight

June 19, 2026
Core Lithium Stock

Core Lithium’s Twin Catalyst: A$290M Funding and Bynoe Acquisition Target 2026 Production

June 19, 2026
Kuros Biosciences Stock

Kuros Biosciences: Revenue Surges 72% But Shares Sink to 52-Week Low

June 19, 2026
Medtronic Stock

Medtronic’s Asian Push and Portfolio Reshuffle Fail to Lift Stock from Its Lows

June 19, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rocket Lab’s New Phase: Index Entry and Robotics M&A Converge to Reshape the Investment Thesis
  • Vital Farms Faces Twin Storms: Legal Investigation and Institutional Flight
  • Core Lithium’s Twin Catalyst: A$290M Funding and Bynoe Acquisition Target 2026 Production

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com